tapebrief
KVUE · Q2 2025

KVUE · Q3 2025 Earnings

Cautious

Kenvue

Reported November 3, 2025

30-second summary

The dominant news today is the separately announced definitive merger agreement under which Kimberly-Clark will acquire all outstanding shares of Kenvue in a cash-and-stock transaction — the quarterly investor call has been cancelled as a result. Against that backdrop, the Q3 print itself shows operational drag widening: organic sales fell 4.4% (Q2 was -4.2%), Asia Pacific revenue collapsed 15.2%, and reported revenue declined 3.5% to $3.76B. Adjusted operating margin contracted 60bps YoY to 21.5% (from 22.1%), in line with the FY guide of margin contraction, and management reaffirmed the $1.00–$1.05 FY2025 EPS range. The Board also named Kirk Perry permanent CEO effective today, removing the "interim" tag he had carried since July 14. For shareholders, the standalone fundamentals now matter less than the deal terms, regulatory path, and exchange ratio mechanics of the Kimberly-Clark transaction.

Headline numbers

EPS

Q3 FY2025

$0.28

Revenue

Q3 FY2025

$3.76B

-3.5% YoY

Gross margin

Q3 FY2025

59.1%

Operating margin

Q3 FY2025

16.7%

Key financials

Q3 FY2025
MetricQ3 FY2025YoYQ2 FY2025QoQ
Revenue$3.76B-3.5%$3.84B-2.0%
EPS$0.28—$0.28-1.8%
Gross margin59.1%———
Operating margin16.7%———

Guidance

Kenvue reaffirms full-year FY2025 guidance with Q3 results tracking to expectations; organic sales decline of -4.4% aligns with 'down low-single-digits' outlook.

Guidance is issued for both next quarter and the full year. Both may appear below.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Organic SalesQ3 FY2025down low-single-digits (full-year expectation)-4.4%in-line with full-year low-single-digit down expectationMet
Adjusted Operating MarginQ3 FY2025expected to contract year-over-year21.5%+0.2pts above prior-year Q3 (implied contraction narrative vs. actual margin resilience)Beat

Segment performance

Q3 FY2025
SegmentQ3 FY2025YoY
Self Care$1.564B-3.8%
Skin Health and Beauty$1.038B-3.2%
Essential Health$1.162B-3.3%

Platform metrics

Q3 FY2025
SegmentQ3 FY2025
Organic Sales Change-4.4%
Volume Decline-4.0%
Foreign Currency Impact+1.0%
Price/Mix Unfavorable Realization-0.4%

Profitability

Q3 FY2025
SegmentQ3 FY2025
Adjusted Gross Margin61.2%
Adjusted Operating Margin21.5%
Adjusted EBITDA Margin23.3%
Interest Expense, Net$93 million

Other KPIs

Q3 FY2025
SegmentQ3 FY2025YoY
North America$1.765B-4.3%
Europe, Middle East, and Africa$0.959B+5.0%
Asia Pacific$0.672B-15.2%
Latin America$0.368B+5.4%

Management tone

No earnings call was held — Kenvue cancelled the previously planned quarterly conference call following the announcement of the Kimberly-Clark merger agreement. The Company has posted prepared remarks on its investor site; tone analysis below is based on the press-release language.

The release language moved one notch more assertive than Q2. Where Perry's July call framed the situation as "self-induced complexity that we need to fix," the Q3 release leads with confidence in "the decisive actions we are taking to accelerate Kenvue's performance" and emphasizes moving with speed to improve operating performance. That framing now has to be read alongside the Kimberly-Clark deal: the "decisive actions" include selling the company. The Board's decision to drop the "interim" tag and name Perry permanent CEO on the same day as the merger announcement signals continuity through what will be a multi-quarter regulatory and integration process rather than a fresh standalone strategy.

Answers to last quarter's watch list

Consumption-vs-organic-sales gap — The Q3 release does not quantify consumption vs. sell-in by segment. Organic sales decelerated from -4.2% to -4.4%, so on the headline number the gap did not close. Status: Continue monitoring, though the standalone metric matters less now that a sale is pending.
Brand portfolio review outcome — The standalone strategic review has effectively been overtaken by the Kimberly-Clark transaction. Status: Superseded by deal
Adjusted operating margin trajectory — Q3 adjusted operating margin contracted 60bps YoY to 21.5%, in line with the FY guide of margin contraction. Gross margin expanded 50bps but increased brand support drove the operating line lower. Status: Tracking as guided
Tariff offset progress — No update on the ~$150M gross annualized tariff impact or specific pricing actions appears in the release.
Continue monitoring
Leadership team completion — Substantially addressed: Kirk Perry named permanent CEO; Carlos De Jesus appointed Group President, North America (succeeding Jan Meurer); Jonathan Halvorson appointed to newly created Chief Digital and Marketing Officer role effective November 17 (the Chief Growth Officer role is being eliminated, and Charmaine England will depart). Status: Resolved

What to watch into next quarter

Kimberly-Clark deal mechanics: exchange ratio, cash/stock mix, expected close timing, regulatory path (antitrust review in US, EU, and key APAC markets), break fee, and any go-shop provisions. These now dominate the KVUE shareholder thesis.

Asia Pacific revenue trajectory: -15.2% YoY in Q3 is a step-change worse than the company average. Watch Q4 for whether the China shipment-timing and customer destocking dynamics cited in the release reverse or persist — material weakness here could affect deal optics and any MAC negotiations.

Volume vs. price/mix decomposition: volume drove essentially all of the -4.4% organic decline. Watch whether Q4 shows any volume stabilization.

FY2025 EPS landing in the range: with three quarters of non-GAAP EPS now visible ($0.28 in Q3), the implied Q4 to hit the $1.00–$1.05 band is achievable but leaves little room for further organic deterioration.

Adjusted operating margin in Q4: Q3's 60bps YoY contraction was in line with guide; watch whether deal-related costs begin to appear as adjustments and whether the underlying margin trend stabilizes.

Sources

  1. Kenvue Q3 FY2025 press release (SEC filing): https://www.sec.gov/Archives/edgar/data/1944048/000194404825000194/q325earningspressrelease.htm
  2. Kenvue / Kimberly-Clark definitive merger agreement announcement (separate release referenced in Q3 press release; posted at investors.kenvue.com)
  3. Kenvue Q2 FY2025 brief (prior-quarter context)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.